Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.14

Margin Of Safety %

Put/Call OI Ratio

1.37

EPS Next Q Diff

0.29

EPS Last/This Y

1.56

EPS This/Next Y

0.34

Price

41.42

Target Price

60.05

Analyst Recom

1.52

Performance Q

-15.24

Relative Volume

1.34

Beta

1.44

Ticker: GH




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04GH50.50.970.0751150
2025-07-07GH49.550.970.1651181
2025-07-08GH50.820.971.6651238
2025-07-09GH51.021.021.0452004
2025-07-10GH51.321.020.2852218
2025-07-11GH50.281.023.9952263
2025-07-14GH49.81.050.1553111
2025-07-15GH48.091.050.4253139
2025-07-16GH47.811.050.1054123
2025-07-17GH47.31.050.0154261
2025-07-18GH46.471.020.2054889
2025-07-21GH45.631.130.3539082
2025-07-22GH46.371.120.1639510
2025-07-23GH45.471.1115.7339951
2025-07-24GH45.491.160.2141126
2025-07-25GH44.451.150.0441218
2025-07-28GH44.281.155.9141362
2025-07-29GH43.441.211.4142633
2025-07-30GH45.211.214.0645524
2025-07-31GH40.951.301.6950822
2025-08-01GH41.41.3712.5052803
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04GH50.50-7.3-14.2-1.99
2025-07-07GH49.51-7.3-4.2-1.99
2025-07-08GH50.82-7.3-21.8-1.99
2025-07-09GH51.04-7.3-13.4-1.99
2025-07-10GH51.29-7.3-13.7-1.99
2025-07-11GH50.25-7.3-5.8-1.99
2025-07-14GH49.77-7.3-8.1-1.99
2025-07-15GH48.09-7.31.3-1.99
2025-07-16GH47.80-7.3-9.4-1.99
2025-07-17GH47.28-7.3-7.5-1.99
2025-07-18GH46.47-7.3-5.2-1.99
2025-07-21GH45.62-7.3-4.8-1.99
2025-07-22GH46.26-7.3-17.0-1.99
2025-07-23GH45.45-7.3-5.1-1.99
2025-07-24GH45.49-7.3-12.1-2.00
2025-07-25GH44.42-7.3-2.7-2.00
2025-07-28GH44.08-7.3-8.9-2.00
2025-07-29GH43.32-7.3-3.6-2.00
2025-07-30GH45.19-7.3-28.3-2.00
2025-07-31GH40.98-8.823.9-2.00
2025-08-01GH41.42-8.8-18.8-2.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04GH-5.550.178.50
2025-07-07GH-5.550.208.50
2025-07-08GH-5.610.208.49
2025-07-09GH-5.610.208.49
2025-07-10GH-5.610.208.49
2025-07-11GH-5.610.207.95
2025-07-14GH-5.610.757.95
2025-07-15GH-5.610.757.95
2025-07-16GH-5.610.757.95
2025-07-17GH-5.610.757.95
2025-07-18GH-5.610.757.95
2025-07-21GH-5.610.747.95
2025-07-22GH-5.610.747.95
2025-07-23GH-5.610.747.95
2025-07-24GH-5.610.747.95
2025-07-25GH-5.610.748.14
2025-07-28GH-5.610.238.14
2025-07-29GH-5.610.238.14
2025-07-30GH-5.610.238.14
2025-07-31GH-5.610.238.14
2025-08-01GH-5.610.238.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.79

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.5

Insider Transactions

-5.61

Institutional Transactions

0.23

Beta

1.44

Average Sales Estimate Current Quarter

226

Average Sales Estimate Next Quarter

244

Fair Value

Quality Score

25

Growth Score

52

Sentiment Score

50

Actual DrawDown %

77.1

Max Drawdown 5-Year %

-91

Target Price

60.05

P/E

Forward P/E

PEG

P/S

6.23

P/B

P/Free Cash Flow

EPS

-3.35

Average EPS Est. Cur. Y​

-2

EPS Next Y. (Est.)

-1.66

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-49.93

Relative Volume

1.34

Return on Equity vs Sector %

111.7

Return on Equity vs Industry %

124.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

-18.8
Guardant Health, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 1999
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
stock quote shares GH – Guardant Health, Inc. Stock Price stock today
news today GH – Guardant Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GH – Guardant Health, Inc. yahoo finance google finance
stock history GH – Guardant Health, Inc. invest stock market
stock prices GH premarket after hours
ticker GH fair value insiders trading